Active specific immunotherapy in malignant melanoma.
暂无分享,去创建一个
R. Gupta | D. Morton | D. Hoon | R. Irie | L. Foshag | Rishab K. Gupta | J. A. Nizze | E. Famatiga | D. B. Hoon
[1] R. Saxton,et al. Gangliosides of human melanoma. , 1987, Journal of the National Cancer Institute.
[2] R. Kempf,et al. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. , 1988, Cancer research.
[3] J. Paulson,et al. Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer antennarius lectin. , 1988, The Journal of biological chemistry.
[4] C. Burtin,et al. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). , 1988, European journal of cancer & clinical oncology.
[5] P O Livingston,et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[6] H. Maguire,et al. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.
[7] N. Pellis,et al. Specific chemoimmunotherapy in tumor‐bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin‐2 , 1986, Cancer.
[8] F. Real,et al. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells , 1985, Cancer.
[9] W. White,et al. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia. , 1985, The New England journal of medicine.
[10] S. Hauser,et al. Book ReviewHealth Care of the Female Adolescent , 1985 .
[11] I. Nath,et al. Characteristics of histamine receptors present on suppressor T cells in "healthy individuals". , 1985, International journal of immunopharmacology.
[12] H. Maguire,et al. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. , 1984, Cancer research.
[13] M. Wallack,et al. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. , 1984, Surgery.
[14] G. Poste,et al. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. , 1984, Journal of immunology.
[15] R. Gupta,et al. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. II. Immunobiologic characterization. , 1984, Journal of the National Cancer Institute.
[16] R. Gupta,et al. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. III. Physicochemical properties. , 1984, Journal of the National Cancer Institute.
[17] R. Gupta,et al. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. I. Purification and development of a radioimmunoassay. , 1984, Journal of the National Cancer Institute.
[18] J. Paulson,et al. Ganglioside GM2 as a human tumor antigen (OFA-I-1). , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[19] R. Bast,et al. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. , 1983, Clinical immunology and immunopathology.
[20] A. Houghton,et al. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells , 1983, International journal of cancer.
[21] F. Bettens,et al. Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. , 1983, Journal of immunology.
[22] E. Korn,et al. Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbent assay in melanoma patients. , 1983, Diagnostic immunology.
[23] J. Paulson,et al. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Engstrom,et al. Augmentation of the human immune response by cyclophosphamide. , 1982, Cancer research.
[25] R. Blaese,et al. Suppressor T-cell function in man: suppression of immunoglobulin production by the direct action of immunoregulatory T cells on the B cell in four separate, distinct systems. , 1982, Clinical immunology and immunopathology.
[26] R. North. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.
[27] S. Suzuki,et al. Mechanism of histamine-induced inhibition of lymphocyte response to mitogens in mice. , 1981, Cellular immunology.
[28] J. Werkmeister,et al. Suppressor cell activity in melanoma patients. I. Relation to tumor growth and immunoglobulin levels in vivo , 1981, International journal of cancer.
[29] M. Mokyr,et al. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. , 1981, Cancer research.
[30] J. Ceuppens,et al. Prostaglandins and the immune response to cancer (review). , 1981, Anticancer research.
[31] W. Terry. Immunotherapy of malignant melanoma. , 1980, The New England journal of medicine.
[32] D. Morton,et al. Oncofoetal antigen I: a target for immune cytolysis of human cancer. , 1979, British Journal of Cancer.
[33] S. Morikawa,et al. Cyclophosphamide eliminates suppressor T cells in age-associated central regulation of delayed hypersensitivity in mice , 1979, The Journal of experimental medicine.
[34] D. Morton,et al. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. , 1978, The Australian and New Zealand journal of surgery.
[35] R. Warren,et al. Antigen mediation of a late-acting suppressor T-cell activity , 1977, The Journal of experimental medicine.
[36] A. Starzinski-Powitz,et al. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes , 1977, The Journal of experimental medicine.
[37] D. Katz,et al. Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide. , 1976, Journal of immunology.
[38] J. Moorhead. Tolerance and contact sensitivity to DNFB in mice. VI. Inhibition of afferent sensitivity by suppressor T cells in adoptive tolerance. , 1976, Journal of immunology.
[39] P. Askenase,et al. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses , 1975, The Journal of experimental medicine.
[40] M. Silverstein,et al. BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience , 1974, Annals of surgery.
[41] R. Gershon. T cell control of antibody production. , 1974, Contemporary topics in immunobiology.
[42] D. Morton,et al. Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.
[43] D. Morton,et al. Demonstration of antibodies against human malignant melanoma by immunofluorescence. , 1968, Surgery.